Written by: Craig Adeyanju
Penny stocks, on the surface, look attractive because they generally have prices under $5. However, many penny stocks belong in that category for a reason and one of them is that they typically lack the trading volume required for them to be attractive to traders.
Low trading volumes almost always mean that the stock is hard to sell. So when you find stocks in this category with high volumes, it may be worthy of an effort to take a deeper look. Here, we look at some high volume penny stocks that you should have on your watchlist.
Note: We used Finscreener's
stock screener to find the penny stocks we're looking at below.
Sesen Bio Inc.
Market Capitalization: $141 million
Average Daily Volume: 2,068,421)
Year-to-Date Stock Performance: -2.11%
Sesen Bio (NASDAQ:
SESN) is a late-stage clinical company involved in the development of targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The excitement around this company is on its lead product candidate Vicinium for the treatment of high-risk non-muscle invasive bladder cancer. In recent months, the company has
announced positive results from its various trials and says it's closer to FDA approval.
New Age Beverages Corporation
Market Capitalization: $141 million
Average Daily Volume: 2,068,421)
Year-to-Date Stock Performance: -2.11%
Sesen Bio (NASDAQ:
SESN) is a late-stage clinical company involved in the development of targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The excitement around this company is on its lead product candidate Vicinium for the treatment of high-risk non-muscle invasive bladder cancer. In recent months, the company has
announced positive results from its various trials and says it's closer to FDA approval.
ViewRay Inc.
Market Capitalization: $258 million
Average Daily Volume: 2,068,421
Year-to-Date Stock Performance: -56.84%
ViewRay Inc. (NASDAQ:
VRAY) is involved in the manufacturing and marketing of radiation therapy systems. Its systems provide real-time imaging during radiation treatments. The company currently has a "Strong Buy" rating from seven of eight analysts. The other one analyst rates VRAY stock a hold.
Geron Corporation
Market Capitalization: $290 million
Average Daily Volume: 2,232,399
Year-to-Date Stock Performance: 54%
Geron Corp. (NASDAQ:
GERN), a clinical-stage biopharmaceutical company, is focused on the development and possible commercialization of telomerase inhibitor, imetelstat. The treatment, developed for hematologic myeloid malignancies, has shown positive signs of being able to suppress the proliferation of malignant cells. In August, Geron started a pivotal phase 3 clinical study to evaluate using imetelstat in the treatment of lower-risk myelodysplastic syndromes (MDS).
In September, the U.S. Food and Drug Administration (FDA) granted imetelstat a Fast Track designation for the treatment of relapsed/refractory myelofibrosis.
Granted, Geron still has a long way to go, especially considering its previous crises like a time the FDA placed its
trials on full and partial holds because of adverse events. However, the upside potential could be massive if the drug makes it to the market. Analysts believe imetelstat is potentially a blockbuster treatment.
Three out of four analysts currently rate GERN stock a "Strong Buy," with the other analysts holding out a "Moderate Buy" rating on the stock.
Related:
3 Top Defensive Stocks for Your Portfolio
